Transcarent valuation, funding and investors
Transcarent works in health and care platform development, based in Denver, United States. Founded in 2020, it has about 956 employees.
- Last round
- Series D · $126M · May 2024
- Valuation at last round
- $2.20B
- Headcount
- 956 · growing
- Grade
- A
- Founded
- 2020
Transcarent valuation today
VCMC values Transcarent at $3.5B today, with a range of $2.4B to $4.1B and a grade of A. The valuation starts from its last funding round, a Series D round in May 2024.
Valuation by date (87 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $16.2M | $5.89M – $44.4M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.3M | $5.94M – $44.8M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.5M | $6.00M – $45.2M | $18.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.6M | $6.05M – $45.6M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 23 Oct 2020 | $223M | $146M – $609M | $400M (+80%) | after a round | – | unknown | C | 0% |
| 1 Nov 2020 | $226M | $146M – $609M | $400M (+77%) | after a round | – | unknown | C | 0% |
| 1 Dec 2020 | $237M | $146M – $609M | $400M (+69%) | after a round | – | unknown | C | 0% |
| 1 Jan 2021 | $249M | $146M – $609M | $400M (+61%) | after a round | – | unknown | C | 0% |
| 1 Feb 2021 | $262M | $146M – $609M | $400M (+53%) | after a round | – | unknown | C | 0% |
| 1 Mar 2021 | $274M | $146M – $609M | $400M (+46%) | after a round | – | unknown | C | 0% |
| 1 Apr 2021 | $288M | $146M – $609M | $400M (+39%) | after a round | – | unknown | C | 0% |
| 1 May 2021 | $302M | $146M – $609M | $400M (+32%) | after a round | – | unknown | C | 0% |
| 1 Jun 2021 | $318M | $146M – $609M | $400M (+26%) | after a round | – | unknown | C | 0% |
| 11 Jun 2021 | $501M | $435M – $863M | $750M (+50%) | after a round | – | unknown | B | 0% |
| 1 Jul 2021 | $512M | $435M – $863M | $750M (+47%) | after a round | – | unknown | B | 0% |
| 1 Aug 2021 | $530M | $435M – $863M | $750M (+42%) | after a round | – | unknown | B | 0% |
| 1 Sep 2021 | $548M | $435M – $863M | $750M (+37%) | after a round | – | unknown | B | 0% |
| 1 Oct 2021 | $567M | $435M – $863M | $750M (+32%) | after a round | – | unknown | B | 0% |
| 1 Nov 2021 | $587M | $435M – $863M | $750M (+28%) | after a round | – | unknown | B | 0% |
| 1 Dec 2021 | $607M | $435M – $863M | $750M (+24%) | after a round | – | unknown | B | 0% |
| 1 Jan 2022 | $628M | $435M – $863M | $750M (+19%) | after a round | – | unknown | B | 0% |
| 12 Jan 2022 | $1.6B | $1.4B – $2.4B | $2.1B (+30%) | after a round | – | unknown | A | 0% |
| 1 Feb 2022 | $1.6B | $1.4B – $2.4B | $2.1B (+28%) | after a round | 180 | unknown | A | 0% |
| 1 Mar 2022 | $1.7B | $1.4B – $2.4B | $2.1B (+26%) | after a round | 180 | unknown | A | 0% |
| 1 Apr 2022 | $1.7B | $1.4B – $2.4B | $2.1B (+23%) | after a round | 180 | unknown | A | 0% |
| 1 May 2022 | $1.8B | $1.4B – $2.4B | $2.1B (+20%) | after a round | 180 | unknown | A | 0% |
| 1 Jun 2022 | $1.8B | $1.4B – $2.4B | $2.1B (+17%) | after a round | 180 | unknown | A | 0% |
| 1 Jul 2022 | $1.8B | $1.4B – $2.4B | $2.1B (+15%) | after a round | 180 | unknown | A | 0% |
| 1 Aug 2022 | $1.9B | $1.4B – $2.4B | $2.1B (+12%) | after a round | 180 | unknown | A | 0% |
| 1 Sep 2022 | $1.9B | $1.4B – $2.4B | $2.1B (+10%) | after a round | 180 | unknown | A | 0% |
| 1 Oct 2022 | $2.0B | $1.4B – $2.4B | $2.1B (+8%) | after a round | 180 | unknown | A | 0% |
| 1 Nov 2022 | $2.0B | $1.4B – $2.4B | $2.1B (+5%) | after a round | 180 | unknown | A | 0% |
| 1 Dec 2022 | $2.0B | $1.4B – $2.4B | $2.1B (+3%) | after a round | 180 | unknown | A | 0% |
| 1 Jan 2023 | $2.2B | $1.4B – $2.6B | $2.3B (+1%) | after a round | 250 | growing | B | 0% |
| 1 Feb 2023 | $2.3B | $1.4B – $2.6B | $2.3B (0%) | after a round | 250 | growing | B | 0% |
| 1 Mar 2023 | $2.3B | $1.4B – $2.6B | $2.3B (0%) | after a round | 250 | growing | A | 0% |
| 1 Apr 2023 | $2.3B | $1.5B – $2.6B | $2.3B (0%) | after a round | 250 | growing | A | 0% |
| 1 May 2023 | $2.3B | $1.5B – $2.6B | $2.3B (0%) | after a round | 260 | growing | A | 0% |
| 1 Jun 2023 | $2.3B | $1.5B – $2.6B | $2.3B (0%) | after a round | 260 | growing | A | 0% |
| 1 Jul 2023 | $2.3B | $1.5B – $2.6B | $2.3B (0%) | after a round | 260 | growing | A | 0% |
| 1 Aug 2023 | $2.3B | $1.5B – $2.6B | $2.3B (0%) | after a round | 260 | growing | A | 0% |
| 1 Sep 2023 | $2.3B | $1.0B – $2.6B | $2.3B (0%) | after a round | 260 | flat | B | 0% |
| 1 Oct 2023 | $2.3B | $1.0B – $2.6B | $2.3B (0%) | after a round | 260 | flat | B | 0% |
| 1 Nov 2023 | $2.3B | $968M – $2.6B | $2.3B (0%) | after a round | 260 | flat | B | 0% |
| 1 Dec 2023 | $2.3B | $932M – $2.6B | $2.3B (0%) | after a round | 260 | flat | B | 0% |
| 1 Jan 2024 | $2.3B | $896M – $2.6B | $2.3B (0%) | after a round | 260 | flat | B | 0% |
| 1 Feb 2024 | $2.3B | $810M – $2.6B | $2.3B (0%) | after a round | 260 | flat | B | 0% |
| 1 Mar 2024 | $2.5B | $1.7B – $2.8B | $2.5B (0%) | after a round | 360 | growing | A | 0% |
| 1 Apr 2024 | $2.5B | $1.7B – $2.8B | $2.5B (0%) | after a round | 360 | growing | A | 0% |
| 1 May 2024 | $2.5B | $1.7B – $2.8B | $2.5B (0%) | after a round | 360 | growing | A | 0% |
| 3 May 2024 | $2.2B | $1.9B – $3.3B | $2.9B (+30%) | after a round | 360 | growing | A | 0% |
| 1 Jun 2024 | $2.2B | $1.9B – $3.3B | $2.9B (+27%) | after a round | 360 | growing | A | 0% |
| 1 Jul 2024 | $2.3B | $1.9B – $3.3B | $2.9B (+25%) | after a round | 360 | growing | A | 0% |
| 1 Aug 2024 | $2.4B | $1.9B – $3.3B | $2.9B (+23%) | after a round | 390 | growing | A | 0% |
| 1 Sep 2024 | $2.4B | $1.9B – $3.3B | $2.9B (+20%) | after a round | 390 | growing | A | 0% |
| 1 Oct 2024 | $2.5B | $1.9B – $3.3B | $2.9B (+18%) | after a round | 390 | growing | A | 0% |
| 1 Nov 2024 | $2.6B | $1.9B – $3.4B | $3.0B (+16%) | after a round | 420 | growing | A | 0% |
| 1 Dec 2024 | $2.6B | $1.9B – $3.4B | $3.0B (+13%) | after a round | 420 | up | A | 0% |
| 1 Jan 2025 | $2.7B | $1.9B – $3.4B | $3.0B (+10%) | after a round | 420 | up | A | 0% |
| 1 Feb 2025 | $2.7B | $1.9B – $3.4B | $3.0B (+8%) | after a round | 420 | up | A | 0% |
| 1 Mar 2025 | $2.8B | $1.9B – $3.4B | $3.0B (+5%) | after a round | 420 | up | A | 0% |
| 1 Apr 2025 | $2.9B | $1.9B – $3.4B | $2.9B (+3%) | after a round | 409 | up | A | 0% |
| 1 May 2025 | $2.9B | $1.9B – $3.4B | $2.9B (0%) | after a round | 409 | up | A | 0% |
| 1 Jun 2025 | $2.9B | $1.9B – $3.4B | $2.9B (0%) | after a round | 409 | up | A | 0% |
| 1 Jul 2025 | $3.0B | $1.9B – $3.5B | $3.0B (0%) | after a round | 462 | up | B | 0% |
| 1 Aug 2025 | $3.0B | $1.9B – $3.5B | $3.0B (0%) | after a round | 475 | up | B | 0% |
| 1 Sep 2025 | $3.0B | $1.9B – $3.5B | $3.0B (0%) | after a round | 475 | up | B | 0% |
| 1 Oct 2025 | $3.1B | $1.9B – $3.5B | $3.1B (0%) | after a round | 492 | up | B | 0% |
| 1 Nov 2025 | $3.1B | $2.1B – $3.6B | $3.1B (0%) | after a round | 545 | growing | A | 0% |
| 1 Dec 2025 | $3.1B | $2.1B – $3.6B | $3.1B (0%) | after a round | 545 | growing | A | 0% |
| 1 Jan 2026 | $3.1B | $2.1B – $3.6B | $3.1B (0%) | after a round | 545 | growing | A | 0% |
| 1 Feb 2026 | $3.1B | $2.2B – $3.6B | $3.1B (0%) | after a round | 545 | growing | A | 0% |
| 1 Mar 2026 | $3.1B | $1.8B – $3.6B | $3.1B (0%) | after a round | 545 | up | B | 0% |
| 1 Apr 2026 | $3.3B | $2.3B – $3.8B | $3.3B (0%) | after a round | 731 | growing | A | 0% |
| 1 May 2026 | $3.3B | $2.4B – $3.8B | $3.3B (0%) | after a round | 731 | growing | A | 0% |
| 1 Jun 2026 | $3.4B | $2.3B – $3.9B | $3.4B (0%) | after a round | 809 | growing | A | 0% |
| 1 Jul 2026 | $3.4B | $2.3B – $3.9B | $3.4B (0%) | after a round | 809 | growing | A | 0% |
| 1 Aug 2026 | $3.4B | $2.3B – $3.9B | $3.4B (0%) | after a round | 809 | growing | A | 0% |
| 1 Sep 2026 | $3.4B | $2.3B – $3.9B | $3.4B (0%) | after a round | 809 | growing | A | 0% |
| 1 Oct 2026 | $3.5B | $2.4B – $4.1B | $3.5B (0%) | after a round | 956 | growing | A | 0% |
| 24 Oct 2026 | $3.5B | $2.4B – $4.1B | $2.9B (-19%) | after a round | 956 | growing | A | 0% |
Key facts about Transcarent
- Founded
- 2020
- Headquarters
- Denver, United States
- Employees
- about 956 +94% in a year
- Total raised
- $424M
- Funding rounds
- 4
- Last round
- Series D May 2024
Transcarent was founded in 2020 by Glen Tullman and Hemant Taneja.
Transcarent funding history
Transcarent has 4 funding rounds on record, from Oct 2020 to May 2024, $424M in total. The latest disclosed valuation is $2.20B post-money (Series D, May 2024).
Series D 2 May 2024
Led by General Catalyst, 7wire Ventures; with Geodesic Capital, Memorial Hermann Health System, Threshold, Kinnevik, Ally Bridge Group, Human Capital, Merck Global Health Innovation Fund, Alta Partners, Leaps by Bayer.
Sources: transcarent.com, transcarent.com, statnews.com and 2 more
$126M
$2.20B post-money
Series C 11 Jan 2022
Led by Kinnevik, Human Capital; with Ally Bridge Group, Northwell Health, Intermountain Healthcare, Rush University Medical Center, General Catalyst, 7wire Ventures, Alta Partners, Merck Global Health Innovation Fund, Jove Equity Partners, Threshold, GreatPoint Ventures.
Sources: transcarent.com, jhconline.com, fiercehealthcare.com
$200M
$1.62B post-money
Series B 10 Jun 2021
Led by General Catalyst, 7wire Ventures; with Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures, Threshold, Alta Partners, Jove Equity Partners.
Sources: transcarent.com, fiercehealthcare.com, finsmes.com
$58M
$500M post-money
Series A 22 Oct 2020
Led by General Catalyst; with 7wire Ventures, Alta Partners.
Sources: transcarent.com, businesswire.com
$40M
Transcarent investors
17 investors have backed Transcarent; 7wire Ventures, General Catalyst and Human Capital and 1 more led at least one round.
- General Catalyst lead, 4 rounds
- Kinnevik lead, 2 rounds
- Merck Global Health Innovation Fund 3 rounds
- Jove Equity Partners 2 rounds
- Leaps by Bayer 2 rounds
- Geodesic Capital
- Intermountain Healthcare
- Kleiner Perkins
- Memorial Hermann Health System
- Northwell Health
- Rush University Medical Center
What Transcarent does
Transcarent works in health care services, with 14 recorded offerings and customers in healthcare.
Transcarent, Inc. is an American company engaged in providing a health and care platform that integrates medical, pharmacy, and point solutions. The company offers services such as virtual care, pharmacy care, surgery care, weight health, cancer care, and second opinion services, supported by AI-powered personalized benefits, health, and care. Transcarent serves employers, labor unions, government consultants, health plans, and individuals across the United States. The company is certified by NCQA, SOC 2 Type II, ISO/IEC 27001, and HITRUST CSF r2.
Description from Veridion's company data.
Products and services
- Health and Care Platform Development
- Virtual Care Services
- Pharmacy Care Services
- Surgery Care Services
- Weight Management Services
- Cancer Care Services
- Second Opinion Services
- AI-Powered Benefits Personalization
- Health and Care Benefits Management
- Clinical Consultation Services
- Member Engagement Services
- Health Outcomes Improvement Services
- Regulatory Compliance Consulting
- Nationwide Health Services
Markets
- Healthcare
Technology
- AI-Powered Personalized Benefits
Certifications
- NCQA accredited
- SOC 2 Type II
- ISO/IEC 27001
- HITRUST CSF r2
Business model
- Business-to-Business
- Business-to-Consumer
- Service Provider
- Software-as-a-Service
- Enterprise
Industry codes (NAICS)
- 621498 All Other Outpatient Care Centers 70% match
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services 30% match
Questions about Transcarent
What is Transcarent worth?
Valuation $3.5B (range $2.4B to $4.1B), as of 24 Oct 2026. The last disclosed valuation was $2.20B (Series D, May 2024).
Has Transcarent raised money?
Transcarent has 4 funding rounds on record, from Oct 2020 to May 2024, $424M in total. The latest disclosed valuation is $2.20B post-money (Series D, May 2024).
Who has invested in Transcarent?
7wire Ventures, General Catalyst, Human Capital, Kinnevik, Alta Partners and Merck Global Health Innovation Fund, and 11 more. Lead investors include 7wire Ventures, General Catalyst, Human Capital and Kinnevik.
How many people work at Transcarent?
About 956, up 94% over the last year. Headcount grew from 180 in Feb 2022 to 956 in Sep 2026.
What does Transcarent do?
Transcarent works in health care services, with 14 recorded offerings and customers in healthcare. Its main offerings are health and care platform development, virtual care services and pharmacy care services.
When was Transcarent founded, and where is it based?
Transcarent was founded in 2020 and is based in Denver, United States. It has about 956 employees, up 94% over the last year.